Rubius Therapeutics market stock research📈, should we short sale $RUBY?
, (GLOBE NEWSWIRE) -- (Nasdaq:RUBY), a biotechnology company pioneering the development of a new class of ready-to-use cellular therapies, today announced the pricing of its initial public offering of 10,483,000 shares of common stock at a public offering price of per share, before underwriting discounts and commissions.
In addition, Rubius has granted the underwriters a 30-day option to purchase up to an additional 1,572,450 shares of common stock at the initial public offering price, less the underwriting discounts and commissions.
Rubius’ common stock is expected to begin trading on The Nasdaq Global Select Market on July 18, 2018, under the ticker symbol “RUBY.” All of the common stock is being offered by Rubius.
The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Rubius, are expected to be $241.1 million, excluding any exercise of the underwriters’ option to purchase additional shares.
The offering is expected to close on July 20, 2018, subject to the satisfaction of customary closing conditions.
J.P. Morgan, , Jefferies, and Leerink Partners are acting as joint book-running managers for the offering.
Registration statements relating to the shares being sold in this offering have been filed with the Securities and Exchange Commission and became effective on July 17, 2018. The offering is being made only by means of a prospectus. Copies of the final prospectus may be obtained, when available, from , c/o , , 11717, telephone: (866) 803-9204, or by emailing [email protected]; , Attention: , 180 , 2nd Floor, New York, NY 10014; , Attention: , , 2nd Floor, 10022, by telephone at (877) 547-6340, or by email at [email protected]; or , Attention: , , 37th Floor, , 02110, by telephone at (800) 808-7525, ext.
6132, or by email at [email protected]
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
is pioneering the development of a new class of medicines, Red Cell Therapeutics, or RCTs.
Rubius has designed a proprietary platform to genetically engineer and culture RCTs that are selective, potent and ready-to-use cellular therapies.
+1 (973) 271-6085
Vice President, Corporate Communications and Investor Relations
+1 (617) 949-5296
Source: Rubius Therapeutics